SG11201700201UA - Combination therapy for cancer - Google Patents

Combination therapy for cancer

Info

Publication number: SG11201700201UA
Authority: SG; Singapore
Prior art keywords: cancer; combination therapy; therapy; combination
Prior art date: 2014-07-11

Application number

SG11201700201UA

Other languages

English (en)

Inventor

Michael Pourdehnad

Anita Gandhi

Kenichi Takeshita

Rajesh Chopra

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-11

Filing date

2015-07-10

Publication date

2017-02-27

2015-07-10 Application filed by Celgene Corp filed Critical Celgene Corp

2017-02-27 Publication of SG11201700201UA publication Critical patent/SG11201700201UA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG11201700201UA 2014-07-11 2015-07-10 Combination therapy for cancer SG11201700201UA (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201462023748P	2014-07-11	2014-07-11
US201462033062P	2014-08-04	2014-08-04
US201462033566P	2014-08-05	2014-08-05
US201562149941P	2015-04-20	2015-04-20
US201562156928P	2015-05-05	2015-05-05
PCT/US2015/039939 WO2016007854A1 (fr)	2014-07-11	2015-07-10	Polythérapie contre le cancer

Publications (1)

Publication Number	Publication Date
SG11201700201UA true SG11201700201UA (en)	2017-02-27

Family

ID=53682893

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201700201UA SG11201700201UA (en)	2014-07-11	2015-07-10	Combination therapy for cancer

Country Status (16)

Country	Link
US (1)	US20170128448A1 (fr)
EP (1)	EP3166635A1 (fr)
JP (1)	JP2017521396A (fr)
KR (1)	KR20170029565A (fr)
CN (1)	CN107073122A (fr)
AU (1)	AU2015287694A1 (fr)
BR (1)	BR112017000556A2 (fr)
CA (1)	CA2954652A1 (fr)
CL (1)	CL2017000050A1 (fr)
EA (1)	EA201790164A1 (fr)
HK (1)	HK1231381A1 (fr)
IL (1)	IL249898A0 (fr)
MX (1)	MX2017000366A (fr)
SG (1)	SG11201700201UA (fr)
WO (1)	WO2016007854A1 (fr)
ZA (1)	ZA201608559B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2009003038A (es)	2006-09-26	2009-04-15	Celgene Corp	Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
UA113512C2 (xx)	2011-03-11	2017-02-10		Тверда форма 3-(5-аміно-2-метил-4-оксо-4h-хіназолін-3-іл)піперидин-2,6-діону і її фармацевтична композиція та застосування
ES2814952T3 (es)	2012-09-04	2021-03-29	Celgene Corp	Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
JP6727237B2 (ja)	2015-07-02	2020-07-22	セルジーンコーポレイション	血液がん及び固形腫瘍の治療のための併用療法
US10159675B2 (en) *	2015-12-02	2018-12-25	Celgene Corporation	Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
WO2019083866A1 (fr)	2017-10-23	2019-05-02	Atara Biotherapeutics, Inc.	Méthodes de gestion de la flambée tumorale liée à l'immunothérapie adoptive
EP3787751A1 (fr)	2018-05-03	2021-03-10	Juno Therapeutics, Inc.	Polythérapie d'une thérapie par lymphocytes t à récepteur antigénique chimérique (car) et d'un inhibiteur de btk
US20230000956A1 (en) *	2019-10-08	2023-01-05	Memorial Sloan Kettering Cancer Center	Combination therapy with glucarpidase with methotrexate/rituximab to treat cns lymphoma
JP7581345B2 (ja)	2019-10-21	2024-11-12	セルジーンコーポレーション	２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを用いて慢性リンパ性白血病を治療する方法
CN115671295B (zh) *	2019-10-21	2025-10-28	新基公司	包含化合物的药物组合物及其使用方法
JP2025503176A (ja) *	2022-01-28	2025-01-30	ジェンマブエー／エス	びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
WO2023220655A1 (fr)	2022-05-11	2023-11-16	Celgene Corporation	Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
WO2024108028A1 (fr) *	2022-11-16	2024-05-23	Salarius Pharmaceuticals, Inc.	Méthodes d'utilisation de composés enrichis en deutérium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001052353A2 (fr) *	2000-01-12	2001-07-19	Emag Technologies L.L.C.	Antenne imprimee omnidirectionnelle compacte et peu onereuse
US7346839B2 (en) *	2003-09-30	2008-03-18	Google Inc.	Information retrieval based on historical data
US20060003059A1 (en) *	2004-07-02	2006-01-05	Burt Tabora	Combined preparation and apparatus for use with a food blender and method for making preparation
TWI423039B (zh) *	2010-07-23	2014-01-11	Quanta Comp Inc	伺服器系統與其操作方法
JP6118273B2 (ja) *	2011-03-11	2017-04-19	セルジーンコーポレイション	免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用
CA2909579A1 (fr) *	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Therapie combinee comprenant un inhibiteur de la kinase tor et du n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide pour le traitement d'un cancer
WO2014172429A1 (fr) *	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Polythérapie comportant un inhibiteur de kinase tor et un composé imid pour le traitement du cancer
EP2986322A1 (fr) *	2013-04-17	2016-02-24	Signal Pharmaceuticals, LLC	Polythérapie comprenant un inhibiteur de kinase tor et un composé de quinazolinone substitué en 5 pour le traitement du cancer
WO2014179661A1 (fr) *	2013-05-03	2014-11-06	Celgene Corporation	Méthodes de traitement du cancer à l'aide d'une polythérapie

2015
- 2015-07-10 CA CA2954652A patent/CA2954652A1/fr not_active Abandoned
- 2015-07-10 WO PCT/US2015/039939 patent/WO2016007854A1/fr not_active Ceased
- 2015-07-10 EP EP15739486.7A patent/EP3166635A1/fr not_active Withdrawn
- 2015-07-10 HK HK17105024.0A patent/HK1231381A1/zh unknown
- 2015-07-10 US US15/323,173 patent/US20170128448A1/en not_active Abandoned
- 2015-07-10 AU AU2015287694A patent/AU2015287694A1/en not_active Abandoned
- 2015-07-10 SG SG11201700201UA patent/SG11201700201UA/en unknown
- 2015-07-10 EA EA201790164A patent/EA201790164A1/ru unknown
- 2015-07-10 KR KR1020177003385A patent/KR20170029565A/ko not_active Withdrawn
- 2015-07-10 JP JP2016574049A patent/JP2017521396A/ja not_active Abandoned
- 2015-07-10 CN CN201580037534.4A patent/CN107073122A/zh active Pending
- 2015-07-10 BR BR112017000556A patent/BR112017000556A2/pt not_active IP Right Cessation
- 2015-07-10 MX MX2017000366A patent/MX2017000366A/es unknown
2016
- 2016-12-12 ZA ZA2016/08559A patent/ZA201608559B/en unknown
2017
- 2017-01-02 IL IL249898A patent/IL249898A0/en unknown
- 2017-01-09 CL CL2017000050A patent/CL2017000050A1/es unknown

Also Published As

Publication number	Publication date
EP3166635A1 (fr)	2017-05-17
CL2017000050A1 (es)	2017-08-11
WO2016007854A1 (fr)	2016-01-14
AU2015287694A1 (en)	2017-02-02
IL249898A0 (en)	2017-03-30
CN107073122A (zh)	2017-08-18
US20170128448A1 (en)	2017-05-11
ZA201608559B (en)	2018-04-25
KR20170029565A (ko)	2017-03-15
EA201790164A1 (ru)	2017-10-31
CA2954652A1 (fr)	2016-01-14
BR112017000556A2 (pt)	2017-11-07
MX2017000366A (es)	2017-04-27
JP2017521396A (ja)	2017-08-03
HK1231381A1 (zh)	2017-12-22

Publication	Publication Date	Title
ZA201702382B (en)	2020-07-29	Combination therapy for cancer
IL254705A0 (en)	2017-11-30	Combination therapy for cancer
PL3553087T3 (pl)	2025-04-28	Terapia celowana nowotworu złośliwego płuc
IL250387A0 (en)	2017-03-30	combined treatment
SI3122358T1 (sl)	2021-04-30	Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
IL249231A0 (en)	2017-02-28	Pharmaceutical combinations for cancer treatment
IL249898A0 (en)	2017-03-30	Combined cancer treatment
GB201405033D0 (en)	2014-05-07	Combination therapy
ZA201702522B (en)	2019-10-30	Combination therapy
IL247859A0 (en)	2016-11-30	Cancer treatment
IL246761A0 (en)	2016-08-31	Combined cancer treatment
GB201519734D0 (en)	2015-12-23	Cancer therapy
GB201508480D0 (en)	2015-07-01	Cancer
ZA201608217B (en)	2019-05-29	Combination therapy
IL259097A (en)	2018-06-28	Combination therapy for cancer
HRP20210383T8 (hr)	2021-11-26	Kombinirana terapija za rak
GB201411884D0 (en)	2014-08-20	Cancer therapy
GB201417819D0 (en)	2014-11-19	Agents for cancer therapy
GB201511609D0 (en)	2015-08-19	Cancer therapy
GB201511121D0 (en)	2015-08-05	Cancer therapy
GB201511120D0 (en)	2015-08-05	Cancer therapy
HK1226650A1 (en)	2017-10-06	Combination therapy for cancer
GB201409457D0 (en)	2014-07-09	Molecules for cancer therapy
GB201406529D0 (en)	2014-05-28	Molecules for cancer therapy
GB201419311D0 (en)	2014-12-17	Combination therapy